Active Shortage Injection Anti-Infective
Rifampin Injection · #17 of 35 active shortages by FDA posting duration
Brand: RIFADIN IV
FDA lists Rifampin Injection as Active Shortage (Sanofi-Aventis U.S. LLC).
Availability on file: Available
Rifampin Injection: Active Shortage
Available 12 shortage presentations are tracked for this drug. Contact your pharmacist if you are affected.
Shortage Details
- Generic Name
- Rifampin Injection
- Manufacturer
- Sanofi-Aventis U.S. LLC
- Dosage Form
- Injection
- Presentation
- Rifadin, Injection, 600 mg/10 mL (NDC 0068-0597-01)
- Package NDC
- 0068-0597-01
Status & Timeline
- Status
- Active Shortage
- Availability
- Available
- First Reported
- Feb 17, 2021
- Last Updated
- Sep 17, 2025
- Therapeutic Category
- Anti-Infective
Row fields from the FDA Drug Shortages database via openFDA.
Full Drug Profile
rifampin
Side effects, interactions, warnings & more
Nearby, Other Rifampin Shortage Records
Rifampin Injection
Mylan Institutional, a Viatris Company
Injection
Rifampin Injection
Fresenius Kabi USA, LLC
Injection
Rifampin Capsule
Epic Pharma, LLC
Capsule
Rifampin Capsule
Epic Pharma, LLC
Capsule
Rifampin Capsule
Epic Pharma, LLC
Capsule
Rifampin Capsule
Epic Pharma, LLC
Capsule